Autolus Therapeutics (AUTL) Enterprise Value (2018 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Enterprise Value data on file, last reported at -$300.7 million in Q4 2025.

• Quarterly Enterprise Value rose 48.86% year-over-year to -$300.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$300.7 million (up 48.86% YoY) and the FY2025 annual result came in at -$300.7 million, up 48.86% from the prior year.
• Enterprise Value grew to -$300.7 million in Q4 2025, from -$367.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$163.4 million in Q3 2022 to a low of -$759.5 million in Q1 2024.
• A 5-year average of -$373.6 million and a median of -$309.3 million in 2021 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2021 — Enterprise Value plunged 39426.21% — and 2025, when it jumped 48.86%.
• Tracing AUTL's Enterprise Value over 5 years: stood at -$310.7 million in 2021, then decreased by 23.2% to -$382.8 million in 2022, then surged by 37.21% to -$240.3 million in 2023, then tumbled by 144.67% to -$588.0 million in 2024, then jumped by 48.86% to -$300.7 million in 2025.
• The last three Enterprise Value figures came in at -$300.7 million (Q4 2025), -$367.4 million (Q3 2025), and -$454.3 million (Q2 2025), per Business Quant data.